



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

KENNETH ANDREW HUGHES ET. AL.

CASE NO.: BA9316USPCT

APPLICATION NO.: 10/540966

CONFIRMATION NO.: 6105

GROUP ART UNIT: 1625

EXAMINER: MORRIS, PATRICIA L.

FILED: JANUARY 21, 2004 (PCT  
FILING DATE) JUNE 29,  
2005 (371 ENTRY DATE)

FOR: CYANO ANTHRANILAMIDE INSECTICIDES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with 37 CFR §1.97 and §1.98, Applicants bring to the attention of the U.S. Patent and Trademark Office the information listed on the enclosed PTO/SB/08A form. A copy of the information, if required, is also enclosed. Consideration of the information is requested under 37 CFR §1.56 and this information is submitted in accord with the provisions of §1.97(c): after the period specified in §1.97(b) but before the mailing of a Final Office Action, or a Notice of Allowance, or any other action that closes prosecution.

Please note that a separate copy of a publication of EP 0 946 508 A1 is not enclosed as it is identical to WO98/28269.

The PTO is authorized to charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company) in order to complete the requirements for consideration of this Supplemental Information Disclosure Statement.


Respectfully submitted,

LINDA D. BIRCH  
Agent for Applicants  
Registration No.: 38,719  
Telephone: (302) 992-4949  
Facsimile: (302) 892-7949

06/12/2006 DTESSEM1 00000104 041928 10540966

01 FC:1806 180.00 DA

Dated: 05 June 2006



Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for USPTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	10/540966
Filing Date	January 21, 2004 (PCT filing date) June 29, 2005 (371 Entry Date)
First Named Inventor	KENNETH ANDREW HUGHES
Group Art Unit	1625
Examiner Name	MORRIS, PATRICIA L.
Attorney Docket Number	BA9316USPCT

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US - 5,998,424	12-07-1999	Robert A. Galemme, Jr. et al.	
	2	US - 6,403,620	06-11-2002	Robert A. Galemme, Jr. et al.	
	3	US - 6,602,895	08-05-2003	Robert A. Galemme, Jr. et al.	
	4	US - 6,548,512	04-15-2003	Donald Joseph Phillip Pinto et al.	
	5	US - 6,020,357	02-01-2000	Donald Joseph Phillip Pinto et al.	
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			
		US -			

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document CountryCode <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
	6	WO98/28269	07-02-1998	DuPont Merck Pharmaceutical Company		<input type="checkbox"/>
	7	WO98/57937	12-23-1998	DuPont Merck Pharmaceutical Company		<input type="checkbox"/>
	8	EP 0 991 625 B1	06-01-2005	Bristol-Myers Squibb Pharma Company		<input type="checkbox"/>
	9	EP 0 946 508 A1	10-06-1999	Bristol-Myers Squibb Pharma Company		<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.